The change from PCOS to PMOS is a small switch in letters. However, it represents a massive shift in how medicine understands a condition affecting millions of women.
After more than a decade of research, one of the most common hormonal conditions affecting women worldwide has a new name. Scientists have officially renamed Polycystic Ovary Syndrome—known for years as PCOS —to Polyendocrine Metabolic Ovarian Syndrome, or PMOS, as of May 11, 2026. Researchers announced the change at the 8th European Congress of Endocrinology in Prague, publishing their findings in The Lancet (a peer-reviewed general medical journal) and marking what many experts are calling a landmark moment in women’s health.
PMOS affects roughly 170 million people globally—about one in eight women of reproductive age—and its own name has long misrepresented it. Professor Helena Teede at Monash University led the renaming effort. It draws on 14 years of research, more than 50 organizations, and over 22,000 survey responses from patients and clinicians across six continents.
READ MORE: LA Asks An Expert: Wait, Do I Have PCOS?
The Problem with “PCOS”
The term “polycystic” was always somewhat of a misnomer. Many people diagnosed with PCOS don’t actually have cysts on their ovaries, and the name’s emphasis on ovaries obscured the condition’s far broader reach. PCOS touches hormonal systems, metabolism, cardiovascular health, dermatology, and mental health, yet its name points almost exclusively to reproductive anatomy.
That mismatch had real consequences. Patients experienced delayed diagnoses and mismanaged care. On the other hand, clinicians placed a disproportionate focus on fertility and overlooked other serious health risks, including insulin resistance, type 2 diabetes, and heart disease. The stigma attached to a condition framed around cysts and ovaries also made it harder for many patients to have their full range of symptoms taken seriously.
Breaking Down the New Name
Each word in PMOS carries weight. “Polyendocrine” captures the complex hormonal imbalances that go beyond the ovaries. “Metabolic” acknowledges the insulin resistance, obesity risk, and cardiovascular complications that affect many patients. “Ovarian” stays in the name to retain the organ’s relevance.
That said, diagnostic criteria remain unchanged. Doctors still require at least two of three factors for a diagnosis: irregular cycles or absent ovulation, elevated androgen levels, and polycystic ovarian morphology detected by ultrasound. Management approaches also stay the same, including lifestyle interventions, medications like metformin, and hormonal treatments.
What Comes Next
The transition won’t happen overnight. A three-year rollout is underway, with educators targeting clinicians and researchers updating guidelines ahead of full adoption in the 2028 international guidelines update. The Endocrine Society and the International Society of Ultrasound in Obstetrics and Gynecology have both endorsed the change.
Advocates and researchers hope the shift will drive earlier diagnoses (particularly for teenagers), more holistic treatment plans, and stronger research funding.
Frequently Asked Questions
PMOS stands for Polyendocrine Metabolic Ovarian Syndrome. It replaces the former name Polycystic Ovary Syndrome, or PCOS.
PCOS was officially renamed PMOS on May 11, 2026 at the 8th European Congress of Endocrinology in Prague. It was led by Professor Helena Teede at Monash University.
The renaming of Polycystic Ovary Syndrome to Polyendocrine Metabolic Ovarian Syndrome is important because it reflects a broader and more accurate understanding of the condition. Experts say the old term “PCOS” overemphasized ovarian cysts and fertility, even though many patients experience metabolic, hormonal, cardiovascular, and mental health symptoms beyond the ovaries. Researchers hope the shift to PMOS will improve awareness, encourage earlier diagnosis, reduce stigma, and lead to more holistic treatment for the millions of women affected worldwide.
No. A diagnosis still requires at least two of three factors: irregular cycles or absent ovulation, elevated androgen levels confirmed clinically or through lab work, and polycystic ovarian morphology detected by ultrasound.
No. Management approaches remain the same. These include lifestyle interventions, medications like metformin, and hormonal treatments.
A three-year rollout is currently underway. Full adoption is expected in the 2028 international guidelines update, with the transition focused on educating clinicians and updating research guidelines.
